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A B S T R A C T
Introduction. Erectile dysfunction (ED) is increasingly recognized as a public health problem. The interaction
between nitric oxide and reactive oxygen species is one of the important mechanisms implicated in the pathophysi-
ological process of ED. Plasma contains various antioxidant components to prevent free-radical injury.
Aim. The aim of this study was to determine and compare the oxidative and antioxidant status of peripheral venous
blood in patients with ED of arteriogenic and non-arteriogenic origin.
Methods. Oxidative stress and antioxidant status were assessed in 40 patients with ED and 20 healthy controls.
Main Outcome Measures. Plasma reactive oxygen metabolite (ROM) concentrations were measured as an indicator
of oxidative stress, and plasma total antioxidant status (TAS) to indicate antioxidant defense.
Results. Plasma ROM concentrations were higher (349.75  53.35 standard deviation [SD] U.Carr vs.
285.43  25.58 U.Carr, P < 0.001) and plasma TAS lower (0.54  0.16 SD mmol/L vs. 0.94  0.28 SD mmol/L,
P < 0.0001) in patients with arteriogenic ED in comparison to those in patients with non-arteriogenic ED. Plasma
ROM and TAS in controls were not signiﬁcantly different from those in non-arteriogenic ED.
Conclusions. This observation may be useful to better understand and distinguish arteriogenic from non-
arteriogenic ED using laboratory tests. In addition, our ﬁndings provide important support for an antioxidant
therapy to try to correct oxidative stress in arteriogenic ED patients. Barassi A, Colpi GM, Piediferro G, Dogliotti
G, Melzi D’Eril GV, and Corsi MM. Oxidative stress and antioxidant status in patients with erectile
dysfunction. J Sex Med 2009;6:2820–2825.
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Introduction
Erectile dysfunction [1] (ED) is deﬁned as theinability to achieve or maintain erections suf-
ﬁcient for satisfactory sexual intercourse. While up
to the 1980s, ED was considered to be primarily
a psychogenic disease, extensive research efforts
have proven that ED is caused by organic disease
in up to 80% of cases [2]. Penile erection results
from the interaction of different physiologic
systems involving the central and peripheral
nervous system, and endothelial and vascular
smooth muscle cells of the corpora cavernosa [3].
There is growing interest among researchers in
the role of oxidative stress in the pathophysiolo-
gical mechanism of ED [4]. The mechanism of
oxidative injury is thought to involve lipid
peroxidation, protein oxidation, DNA oxidation,
decreased synthesis, and bioavailability of nitric
oxide (NO), which is probably the principal neu-
rotransmitter mediating penile erection [5,6].
Free-radical injury is prevented by exogenous
antioxidants, such as vitamins E and C, and also
by endogenous antioxidants, such as scavenger
enzymes (superoxide dismutase, catalase, and
glutathione peroxidase), bilirubin, and uric acid.
Under some conditions, increases in oxidants and
decreases in antioxidants cannot be prevented, and
the oxidative/antioxidative balance shifts toward
the oxidative status. Basic scientiﬁc studies indicate
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that oxidative stress may have a role in impaired
cavernosal function, such as in ED [7,8]. The aims
of this study were to compare the metabolic status
of patients with arteriogenic and non-arteriogenic
ED, and to assess the metabolic differences
between the two and the healthy subjects.
Material and Methods
Investigation Protocol
In our center, patients complaining of ED are cur-
rently investigated by careful history-taking and
clinical andrological examination, then, a few days
later, by a panel of examinations, including blood
tests, complete blood picture, hemoglobin, gly-
cated hemoglobin, glycemia, urea, creatinine,
C-reactive protein (CRP), total cholesterol and
HDL, triglycerides, transaminases, testosterone,
prolactin, estradiol, urine analysis and 24 hours
microalbuminuria, the International Index of
Erectile Function questionnaire (IIEF), and echo-
color-Doppler of both cavernous arteries.
The IIEF questionnaire [9] is a validated, self-
administered tool [9,10], but we only evaluated the
answers to the ﬁrst 5 (erectile response dominium)
of the 15 questions (IIEF–15, 1–5).
Penile echo-color-Doppler was done in basal
conditions and after intracavernous injection of
10 mcg prostaglandin E1 (PgE1), and the peak
systolic velocity (PSV) and end-diastolic velocity
(EDV) were recorded 5, 10, 15, 20, and 25 minutes
after the injection in the proximal portion of
the penis. Patients were classiﬁed as “non-
arteriogenic” when their PSV was35 cm/second,
or 35 cm/second but >25 cm/second with con-
comitant EDV 0 cm/second, and “arteriogenic”
when their PSV was20 cm/second. The erection
quality was estimated 20 minutes after each injec-
tion. If a patient appeared stressed, he was given a
second injection of the same dose of PgE1 and all
measurements were repeated.
From 30 to 60 minutes after the penile echo-
color-Doppler, participants were placed in a supine
position and blood samples were drawn from a
cubital vein intoEDTA tubes. Samples were imme-
diately stored on ice and centrifuged at 4°C,
3,000 rpm, for 10 minutes. The plasma samples
were separated and stored at -80°C until analysis.
Reactive Oxygen Metabolites (ROMs) and Total
Antioxidant Status (TAS) Testing
ROMs were measured in plasma by a spectropho-
tometric assay (d-ROMs test, Diacron, Italy),
kindly provided by the manufacturers and used
following their instructions. The test measures the
plasma levels of ROMs such as hydroperoxides
generated in cells as a consequence of the respira-
tory burst. The test exploits the hydroperoxides’
ability to generate free radicals in the presence of
transition metals (Fe, Cu, etc.) that act as catalysts.
When free radicals react with a correctly buffered
chromogenic substance, they develop a colored
complex that can be measured photometrically at
505 nm (UVICAM, Cambridge, UK). The con-
centration of the colored complex is directly pro-
portional to the concentration of hydroperoxides.
Results are expressed in arbitrary units, called
Caratelli Units (U.Carr). One U.Carr corresponds
to 0.08 mg of H2O2 per 100 mL.
High levels of ROM indicate oxidative stress.
Low concentrations have been reported during
antioxidant supplementation or in patients under
treatment with corticosteroids [11].
According to the end-point analysis, the absor-
bances must be measured after incubating a solu-
tion of 5 mL of plasma, 1 mL of chromogenic
mixture, and 10 mL of acetate buffer at 37°C for 75
minutes. The intra-assay coefﬁcient of variation
(CV) on 20 samples of a fresh plasma pool was
2.2%, and the inter-assay CV, measuring in 10
different days the same plasma samples stored
frozen, was 3.7%. Accuracy was evaluated using
a control serum with assigned value, provided by
the manufacturer. The method was linear up to
500 U.Carr.
The TAS in the plasma in mmol/L was estab-
lished with the RANDOX NX2332 test
(RANDOX Laboratories Ltd., Ardmore, UK).
The method is based on incubation of ABTS® (2,2
azinobis 3-ethylbenzthiazoline sulfate) with met-
myoglobin and H2O2, which may lead to the for-
mation of ABTS-derived radicals. These have a
stable blue-green color at the wavelength of
600 nm. Antioxidants in the sample weaken the
color in proportion to their concentration. The
test included phosphate buffer (5 mmol/L,
pH 7.4), met-myoglobin (6.1 mmol/L), and hy-
drogen dioxide (250 mmol/L). Absorbance was
recorded after incubation of 3 minutes at 37°C at
600 nm using a spectrophotometer (UVICAM,
Cambridge, UK). The intra-assay coefﬁcient of
variation (CV) on 20 samples of a fresh plasma
pool was 3.6% and the inter-assay CV, measuring
in 10 different days the same plasma sample stored
frozen, was 6.0%. To avoid the effect of a diurnal
variation of ROM and TAS, the eco-color Doppler
procedure and drawing the blood samples were
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done between 9:00 and 12:00 am to the entire
population [12]. The possible consequences of the
stress, injection, and needle trauma were not dif-
ferent in the two populations because all the
patients were investigated in the same way.
Patients and Control Group
Out of a series of 228 ﬁled ED cases studied in the
period October 2005–June 2007, we randomly
selected 20 arteriogenic patients (group A) and 20
non-arteriogenic patients (group B), according to
our inclusion criteria for this study, for a total of 40
cases (mean age 44 years, range 24–60 years). The
inclusion criteria were: no clinical evidence from
the patient’s clinical history of coronary artery
disease, hypertension, malignancy, renal failure,
congestive heart failure, systemic inﬂammatory
disease, or arrhythmias, and no current smoking
[13] and no vitamins supplementation. We
excluded even the subjects affected by diabetesmel-
litus because the redox status of these patients has
already been deeply investigated: in these patients,
macro- and micro-angiopathy are related, not only
to oxidative stress, but also to endothelial impair-
ment [14].
The 20 healthy controls were all blood donors
(mean age 42.1 years, range 25–53 years), and,
according to their answers to the ﬁrst ﬁve IIEF–15
questions (erectile response domain), did not
suffer from ED. Both healthy controls and the
patients of the two groups declared to develop a
normal physical activity.
In accordance with the Declaration of Helsinki
II, the design of the study was explained thor-
oughly to all participants, and informed consent
was obtained for ROM and TAS testing from all
the 228 ﬁled ED patients and the 20 controls, and
for administering the IIEF-15 test to controls. In
particular, it was explained to the participants that
no additional blood was needed for this study.
Statistical Analysis
The results are given as mean  standard devia-
tion (SD). Groups were compared by one-way
analysis of variance. Linear regression analysis was
also done between experimental variables. Signiﬁ-
cance was established as P < 0.05. Post hoc com-
parisons in logical sets of means were done using
the Tukey–Kramer multiple comparisons test
(Instat, GraphPAd, CA, USA).
Results
In Group A (20 arteriogenic ED men; mean age 48
years, range 26–59 years), IIEF values were: mean
10.30, median 11.00 (range 0–20). In Group B (20
non-arteriogenic ED men; mean age 41 years,
range 24–60 years), the respective ﬁgures were
12.75 and 14.00 (range 0–20). There were no sig-
niﬁcant differences between the two groups
(P > 0.05).
ROM, a parameter of oxidative stress, was
determined in the plasma of ED patients. Plasma
ROM concentrations were signiﬁcantly higher in
Group A than in Group B (349.75  53.35 SD
U.Carr vs. 285.43  25.58 SD U.Carr, P < 0.001),
and than in the controls (257.7  15.96 SD
U.Carr, P < 0.001). There were no appreciable
differences between Group B and the controls
(P > 0.05) (Figure 1).
The plasma TAS concentration, a measure
of the antioxidant status, was lower in Group A
than in Group B (0.54  0.16 SD mmol/L vs.
0.94  0.28 SD mmol/L, P < 0.0001) and also
than in the controls (1.06  0.24 SD mmol/L,
P < 0.0001). There were no signiﬁcant differences
between Group B and the controls (P > 0.05)
(Figure 2).
The plasma CRP level was not signiﬁcantly
different (P > 0.05) between Group A
(3.3  0.7 mg/L) and Group B (2.9  0.9 mg/L).
Discussion
This study shows a typical pattern of oxidative
stress in patients with arteriogenic ED. We found
a signiﬁcant increase of ROM plasma levels and a
simultaneous signiﬁcant decrease of plasma TAS
concentration in arteriogenic ED subjects com-
pared to non-arteriogenic ED subjects and healthy












Figure 1 Reactive oxygen metabolites (ROMs) expressed
in U.Carr (mean  SD). The figure shows the differences
between Group A (men with arteriogenic erectile dysfunc-
tion), Group B (non-arteriogenic erectile dysfunction), and
controls. The ROM concentrations were significantly higher
in Group A than in Group B (P < 0.001), and than in the
controls (P < 0.001). There were no appreciable differences
between Group B and the controls (P > 0.05).
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non-ED controls. The populations studied, ED
and non-ED, were homogeneous and without
any atherosclerotic risk factors. Considering that
ROM reﬂects the amount of oxidative stress and
TAS a measure of the antioxidant status, our data
indicate the presence of an imbalance between
pro-oxidant and the protective mechanisms con-
ferred by antioxidants only in arteriogenic ED
patients.
Erectile dysfunction is a widespread health
problem with an estimated worldwide prevalence
of more than 150 million cases in 1995, which will
increase to approximately 322 million by 2025
[15]. The functional state of the penis is regulated
by the balance of vasoactive substances, which
either contract or relax the vessels and smooth
muscle cells in the corpora cavernosa [16]. Func-
tional and expression studies suggest that NO,
derived from vascular endothelial and neural
sources, plays an essential role in the early steps of
the normal cascade of relaxation of the penile vas-
culature and cavernous smooth muscle [5,3,17].
The interaction between NO and ROM is one
of the important mechanisms implicated in the
pathophysiological process of ED [18]. The pres-
ence of oxygen-free radicals inactivates NO and,
therefore, reduces the effective NO concentration
available for cavernosal muscle relaxation. The
data presented in this report support the hypoth-
esis that the increased oxidative stress, together
with decreased antioxidant status, contributes at
least in part to ED of arteriogenic origin. The
number of patients included in this study may
seem low, but it must be considered that the popu-
lation studied is very selected. In this way, we could
compare the metabolic status of patients with arte-
riogenic and not arteriogenic ED without any con-
founding factors. The population studied had no
clinical evidence of atherosclerotic diseases and
was free of the common risk factors associated
with generalized penile arterial insufﬁciency like
hypertension, hyperlipidemia, cigarette smoking,
diabetes mellitus, and pelvic irradiation [19,20].
However, only arteriogenic ED subjects had
increased ROM and decreased TAS concentra-
tions if their sources in the penis remain largely
unknown [21]. A fairly recent study showed that
plasma TAS of peripheral blood may reﬂect the
TAS of penile cavernosal blood [22]. In conclu-
sion, oxidative stress seems to be a common com-
ponent of arteriogenic ED in line with data
recently reported by Musicki and Burnett [23].
On the possible clinical relevance of these ﬁnd-
ings, we propose that the TAS and ROM assays
might serve as indicators of metabolic status in all
ED patients. When antioxidant levels are mea-
sured in plasma, it is not possible to determine the
origin of these molecules. The question remains
whether antioxidant abnormalities represent the
proverbial egg or chicken dilemma. It appears
likely that these changes are not the cause, but
might be the consequence of the ROM excess.
Thus, the oral supplementation of antioxidants
may be an effective approach, and the arteriogenic
ED subjects may beneﬁt from an antioxidant treat-
ment [24]; otherwise, the treatment of sildenaﬁl
citrate could be useful for its protective effects on
oxidative stress by inhibiting free-radical forma-
tion and by supporting an antioxidant redox
system, as recently reported [25].
Conclusions
Caution must be exercised in ascribing causality
when increased free-radical activity is found to be
associated with disease processes, as oxidative
damage may be a consequence rather than a cause
of tissue injury [26]. However, these purely pre-
liminary ﬁndings do appear to conﬁrm that
increased generation of free radicals and deﬁcien-
cies of antioxidant defense can be an important
etiological factor in vascular ED. Quite likely, the
high plasma ROM levels precede the reduction in
PSV in the cavernous arteries, shown by echo-
color-Doppler examination. Longitudinal studies
are currently in progress to see whether changes in
endothelial dysfunction after antioxidant treat-
ment can delay the appearance of major vascular
complications in impotent patients.













Figure 2 Total antioxidant status (TAS) expressed in
mmol/L (mean  SD). The figure shows the differences
between Group A (men with arteriogenic erectile dysfunc-
tion), Group B (non-arteriogenic erectile dysfunction), and
controls. The TAS concentration was lower in Group A than
in Group B (P < 0.0001), and also than in the controls
(P < 0.0001). There were no significant differences between
Group B and the controls (P > 0.05).
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